The novovax vaccine accounts for more than 90% of US trials

Novavox today (14) released the results of the last phase of testing the vaccine candidate against Kovit-19. Clinical testing centered in the United States (USA) shows that the vaccine is more than 90% effective against the disease and provides protection against variants.

The study included 3,000 volunteers in the United States and Mexico. The company will receive emergency approval from U.S. health officials and will do the same in other countries in the third quarter of this year.

NovaVox’s vaccine candidate has acted more than 93 percent against major Covit-19 strains, a concern among scientists and public health officials, the company said.

During the experiment, the B.1.1.7 variant, first detected in the UK, became the most common variant in the United States.

Among the participants in the study were the first species found in Brazil, South Africa and India, Nova Vox’s head of research and development Gregory Glenn told Reuters.

The vaccine was 91% effective among volunteers at high risk of acute infections and was 100% effective in preventing moderate to severe cases of Govit-19. It was about 70% effective against variants not recognized by NovaVox, Glenn said.

“In practice, it is very important that the vaccine can protect against a highly contagious virus,” he said.

Novavox reported that the vaccine was generally well-tolerated among participants. Side effects include headaches, fatigue and muscle aches, which are usually mild. A small number of participants reported side effects described as severe.

NovaVox is on track to produce 100 million doses per month by the end of the third quarter of 2021 and 150 million doses per month by the fourth quarter of 2021.